-- 蒙特利尔银行(BMO)表示,加拿大3月份的劳动力调查(LFS)显示,工资同比增长4.7%,创下自2024年10月以来的最高增速,这一数字令人意外。 该银行指出,自那时以来的大约一年半时间里,就业市场显著放松,首先是由于过去的货币紧缩政策,然后是由于与美国的贸易战带来的经济逆风——所有这些都发生在移民政策发生重大转变的背景下。 BMO表示,在这样的背景下,单月工资增长加速0.7个百分点确实引人注目。 加拿大统计局解释说,这是由于职业构成和工作年限的变化而产生的统计异常。换句话说:工资加速增长是因为更多的人从事了更高薪的工作,或者工作时间更长,因此获得了更高的收入。考虑到这些因素,年增长率为3.6%,与过去四个月相比变化不大。 该银行表示,这与一些宏观趋势相符:近期净移民外流对低收入工作的劳动者——换句话说,就是临时外籍劳工和学生——的影响尤为严重。 BMO指出,加之人口老龄化,这也可能导致员工群体向那些工作年限较长的人群倾斜。 该银行补充道,尽管如此,这种转变在上个月突然发生仍然令人惊讶。BMO表示将密切关注这一趋势是否会持续。目前看来,实际工资增长似乎比公布的增长率要低。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.